Back to search

Switzerland· 67402001

Rubraca 200 mg, Filmtabletten

A rucaparib product containing rucaparibum, registered in Switzerland by mmpharm GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01XK03

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedRubraca 200 mg, FilmtablettenATCL01XK03REGISTER NO.67402001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Rucaparib is registered in 10 of 19 countries.

Countries holding a registration under ATC L01XK03 (rucaparib), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Rucaparib · ATC L01XK03

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rucaparib costs, country by country.

Normalised to the WHO defined daily dose (1.2 g), so markets compare like for like.

  • Switzerland: $240.27 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Rucaparib · price per daily dose (1.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$240.27
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
rucaparibum
Manufacturer
mmpharm GmbH
Country
Switzerland (CH)
ATC code
L01XK03
ATC class
Rucaparib
Defined daily dose
1.2 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680674020011
    Ds 60 Stk
    CHF 1999.4

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

692 interactions on record for rucaparib.

Graded by severity as the source publishes them — 103 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Rucaparib · interactions on record

692 records

  • 103 severe
  • 576 moderate
  • 13 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rucaparib in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rucaparib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Rubraca
  • Liechtenstein · Rubraca
  • Norway · Rubraca

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c0138b42-b920-4016-92fb-642d4d8d7fd9
GET /v1/drugs/c0138b42-b920-4016-92fb-642d4d8d7fd9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "rucaparibum 200 mg",
  "valid_from": "2024-03-01",
  "limitations": "[{\"description\":\"Nur nach Verordnung durch einen Facharzt der Gynäkologie oder Onkologie und nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes zur Monotherapie im Sinne einer Erhaltungstherapie bei erwachsenen Patientinnen mit BRCA-mutiertem fortgeschrittenem, platinsensitivem, rezidiviertem, high-grade (hochgradig entdifferenziertem) serösem Ovarial-, Eileiter- oder primärem Peritoneal-Karzinom, im Anschluss an eine platinbasierte Chemotherapie bei Vorliegen einer vollständigen oder partiellen Remission unter folgenden Voraussetzungen:<br>\\n<br>\\n• ≥ 2 platinbasierte Chemotherapien, letzte platinhaltige Chemotherapie mit ≥ 4 Zyklen.<br>\\n&nbsp o Nach der letzten Behandlung muss die Patientin ein CA-125 < ULN aufgewiesen haben.<br>\\n• Keine vorangehende Behandlung/Erhaltungstherapie mit PARP-lnhibitoren. Hiervon ausgenommen ist ein verträglichkeitsbedingter Wechsel in derselben Behandlungslinie auf einen anderen PARP-Inhibitor.<br>\\n<br>\\nDie Behandlung erfolgt bis zur Progression.<br>\\n<br>\\nKombinierte oder sequentielle Therapien wie beispielsweise Bevacizumab und Rucaparib oder lmmunonkologika und Rucaparib sowie Retreatments in höheren Behandlungslinien nach einem weiteren Rückfall sind von einer Vergütung ausgeschlossen.<br>\\nIn den ersten 24 Monaten erfolgt die Höhe der Vergütung zu den SL-Preisen. Die Zulassungsinhaberin vergütet bei einer Therapiedauer > 24 Monate ab dem Monat 25 nach Aufforderung durch denjenigen Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, für jede weitere bezogene Packung Rubraca 50% des Fabrikabgabepreises zurück.<br>\\nDie Mehrwertsteuer kann nicht zusätzlich zu diesem Anteil des Fabrikabgabepreises zurückgefordert werden. Die Aufforderung zur Rückvergütung soll in der Regel innerhalb von 6 Monaten nach Verabreichung erfolgen.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21130.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-03-01\",\"validTo\":\"2027-02-28\"}]",
  "galenic_form": "Filmtabl 200 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2021-07-01",
  "self_retention_pct": 10
}

See everything about rucaparib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.